| Notifications | Pegloticase (Krystexxa®) | 08.01.02h | 2/24/2023 10:00 AM | 3/27/2023 | | | 2/24/2023 | Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Notifications | Ventricular Assist Devices (VADs) | 11.02.16u | 2/28/2023 11:00 AM | 5/29/2023 | | | 2/28/2023 | Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | |
| New Policies | olipudase alfa-rpcp (Xenpozyme™) | 08.01.96 | | 2/13/2023 | | | 2/13/2023 | This is a New Policy. | | |
| Updated Policies | Cochlear Implantation | 11.01.02q | 11/7/2022 10:00 AM | 11/7/2022 | 11/7/2022 | | 2/6/2023 | Medical Coding | | |
| Updated Policies | Neuropsychological Testing for Neurologically Based Conditions | 07.03.08m | 11/7/2022 10:00 AM | 2/6/2023 | | | 2/6/2023 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Blinatumomab (Blincyto®) | 08.01.21f | | 2/27/2023 | | | 2/27/2023 | Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Lower Limb Prostheses | 05.00.59l | | 2/27/2023 | | | 2/27/2023 | Coverage and/or Reimbursement Position;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Eptinezumab-jjmr (VYEPTI™) | 08.00.45c | | 2/27/2023 | | | 2/27/2023 | Medical Necessity Criteria | | |
| Reissue Policies | Computer-assisted Musculoskeletal Surgical Navigational Orthopedic Procedure | 11.14.17e | | 1/1/2021 | 2/8/2023 | | 2/8/2023 | | | |
| Reissue Policies | Low-Level laser Therapy | 07.00.14g | | 9/30/2019 | 2/8/2023 | | 2/8/2023 | | | |
| Reissue Policies | evinacumab-dgnb (Evkeeza™) | 08.01.76b | | 10/1/2021 | 2/8/2023 | | 2/8/2023 | | | |
| Reissue Policies | crizanlizumab-tmca (Adakveo®) | 08.00.04 | | 11/30/2020 | 2/8/2023 | | 2/8/2023 | | | |
| Reissue Policies | Composite Tissue Allotransplantation of the Hand(s) and Face | 11.14.30 | | 5/19/2017 | 2/22/2023 | | 2/22/2023 | | | |
| Reissue Policies | Hair Transplants and Cranial Prostheses (Wigs) | 11.08.01g | | 9/9/2019 | 2/22/2023 | | 2/22/2023 | | | |
| Reissue Policies | Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis | 11.16.06j | | 1/1/2020 | 2/22/2023 | | 2/22/2023 | | | |
| Reissue Policies | Routine Foot Care for Certain Medical Conditions | 07.07.01q | | 10/1/2021 | 2/22/2023 | | 2/22/2023 | | | |
| Reissue Policies | Nerve Fiber Density Testing | 06.02.38d | | 1/1/2019 | 2/22/2023 | | 2/22/2023 | | | |
| Reissue Policies | Natalizumab (Tysabri®) | 08.00.64g | | 10/21/2019 | 2/22/2023 | | 2/22/2023 | | | |
| Reissue Policies | Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal Conditions | 11.14.13h | | 1/1/2022 | 2/22/2023 | | 2/22/2023 | | | |
| Reissue Policies | Computer-Aided Detection (CAD) System for Use with Chest Radiographs | 09.00.42c | | 3/11/2015 | 2/22/2023 | | 2/22/2023 | | | |
| Reissue Policies | Application and Removal of Tattoos | 11.08.05g | | 7/20/2012 | 2/22/2023 | | 2/22/2023 | | | |
| Reissue Policies | Manipulation Under Anesthesia | 11.14.24b | | 4/30/2018 | 2/22/2023 | | 2/23/2023 | | | |
| Reissue Policies | Non-Surgical Spinal Decompression Therapy | 07.08.01f | | 3/28/2016 | 2/22/2023 | | 2/23/2023 | | | |
| Reissue Policies | Percutaneous Intradiscal Annuloplasty (IDET/PIRFT) | 11.14.14e | | 7/1/2013 | 2/22/2023 | | 2/23/2023 | | | |
| Reissue Policies | Percutaneous Discectomy | 11.15.15g | | 12/1/2017 | 2/22/2023 | | 2/23/2023 | | | |
| Coding Update | Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus | 00.10.39p | | 1/1/2023 | | | 2/10/2023 | | | |
| Coding Update | Care Management and Care Planning Services | 00.01.59m | | 1/1/2023 | | | 2/10/2023 | | | |
| Coding Update | Consultation Services | 00.01.69b | | 1/1/2023 | | | 2/10/2023 | | | |
| Coding Update | Direct Access to Obstetrics/Gynecology (OB/GYN) Services | 00.09.01j | | 1/1/2023 | | | 2/13/2023 | | | |
| Coding Update | Pharmacogenetics and Metabolite Monitoring for Using Azathioprine (AZA)/6-Mercaptopurine (6-MP) Therapy (Independence Administrators) | 06.02.18m | | 1/1/2023 | | | 2/16/2023 | | | |
| Coding Update | Genetic Testing (Independence Administrators) | 06.02.35ai | | 1/1/2023 | | | 2/16/2023 | | | |